Drug

Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug

4 monthes ago   |   By Xconomy

Two weeks after MorphoSys filed for FDA review of its experimental treatment for a form of lymphoma, the company has struck a deal with Incyte to further develop and commercialize the therapy in the US and around the world. According to financial terms announced Monday, Incyte is paying MorphoySys $750 million up front for the right to co-commercialize the drug tafasitamab in the US, where profits will be split equally. In addition, Wilmington, DE-based Incyte will buy $150 million worth of MorphoSys stock at an unspecified premium. The deal also gives Incyte the right to...
Read more ...

 


Search by Tags

   Drug      Drugs      Therapies      Europe blog main      Europe top stories      National      National blog main      National top stories      Bendamustine      Biotech      CAR-T      Chemotherapy      Chronic Lymphocytic Leukemia      Clinical trials      Diffuse Large B-Cell Lymphoma      FDA      Follicular lymphoma      Geoffrey Porges      Immunotherapy      Incyte      Lenalidomide      Life Sciences      Lymphoma      Lymphoma Research Foundation      Marginal zone lymphoma      MorphoSys      Parsaclisib      Rituximab      SVB Leerink      Tafasitanib  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Merck Outlines COVID-19 Ambitions With Buyout Deal, Collaborations

Merck Outlines COVID-19 Ambitions With Buyout Deal, Collaborations

Merck exited the holiday weekend with some fireworks of its own, announcing three major programs on Tuesday all related to investments in finding ways to treat and prevent... Read more ...

Insitro Adds $143M to Fuel Machine Learning-Driven Drug Development

Insitro Adds $143M to Fuel Machine Learning-Driven Drug Development

A stem cell biologist, a gene editing expert, and a data engineer walk into a room...and that's just a few of the people Daphne Koller has recruited in the past two years to... Read more ...

Site of LUX-ZEPLIN Dark Matter Search Project Carefully Ramps Up Science Work

Site of LUX-ZEPLIN Dark Matter Search Project Carefully Ramps Up Science Work

A photomultiplier tube array that is part of the LUX-ZEPLIN experiment at the Sanford Underground Research Facility in Lead, South Dakota. The photomultiplier tubes are... Read more ...

Viacyte Adds $27M to Move Ahead Trio of Stem Cell Diabetes Treatments

Viacyte Adds $27M to Move Ahead Trio of Stem Cell Diabetes Treatments

Privately held biotech ViaCyte has banked $27 million, the majority an installment of cash from a tranched $80 million Series D financing round it closed in late 2018. The... Read more ...

COVID-19 Sparks New Opportunities for Digital Health Companies

COVID-19 Sparks New Opportunities for Digital Health Companies

Clinicians and regulators are rethinking how healthcare is provided amid precautions prompted by COVID-19. In-person physician visits don't fit within the physical distancing... Read more ...

Bristol Myers Squibb Company: Associate Director of San Diego Global Capital...

Bristol Myers Squibb Company: Bristol-Myers Squibb is a global Biopharma company committed to a single mission: to discover, develop, and deliver innovative medicines focused... Read more ...

Sorrento Receives FDA IND Clearance to Initiate a Phase I Clinical Trial of...

SAN DIEGO, May 26, 2020 - Sorrento Therapeutics, Inc. today announced it has received clearance from the U.S. Food and Drug Administration for its investigational new drug... Read more ...

Public Disclosure of COVID-19 Cases Is More Effective than Lockdowns

Read more ...

Gerald Joyce elected to Royal Swedish Academy of Sciences

LA JOLLA-Salk Professor Gerald Joyce, a pioneer in the field of in vitro evolution, has been elected to the prestigious Royal Swedish Academy of Sciences as a foreign member... Read more ...

Sugars that coat proteins are a possible drug target for pancreatitis

LA JOLLA-Pancreatitis is an inflammation of the pancreas that accounts for 275,000 hospitalizations in the United States annually. Patients who suffer from hereditary... Read more ...